Intellia is a genome editing company, focused on the development of proprietary, potentially curative therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system. This technology offers the potential to develop curative therapeutic options for patients with chronic diseases by addressing the underlying cause of the disease. Intellia's combination of deep scientific expertise and clinical development experience, along with our leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products.

Employee Rating

3.3More
TypePublic
HQCambridge, US
Founded2014
Size (employees)104 (est)+71%
Websiteintelliatx.com
Intellia Therapeutics was founded in 2014 and is headquartered in Cambridge, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Intellia Therapeutics

Nessan Bermingham

Nessan Bermingham

Co-Founder

Intellia Therapeutics Office Locations

Intellia Therapeutics has an office in Cambridge
Cambridge, (HQ)
40 Erie St Ste 130
Show all (1)
Report incorrect company information

Intellia Therapeutics Financials and Metrics

Intellia Therapeutics Revenue

USD

Net income (Q3, 2018)

(22.7m)

EBIT (Q3, 2018)

(24.1m)

Market capitalization (4-Dec-2018)

712.5m

Closing stock price (4-Dec-2018)

16.4

Cash (30-Sep-2018)

293.2m
Intellia Therapeutics's current market capitalization is $712.5 m.
Annual
USDFY, 2016FY, 2017

General and administrative expense

16.8m28.0m

R&D expense

31.8m67.6m

Operating expense total

48.6m95.7m

EBIT

(32.2m)(69.6m)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

General and administrative expense

3.2m3.7m4.7m5.7m6.4m5.7m7.4m7.8m8.3m

R&D expense

5.2m7.4m7.9m13.4m15.6m17.5m22.5m23.5m23.2m

Operating expense total

8.5m11.2m12.6m19.2m21.9m23.2m29.9m31.3m31.5m

EBIT

(6.7m)(6.9m)(7.7m)(12.9m)(16.0m)(15.9m)(22.4m)(23.6m)(24.1m)
Annual
USDFY, 2016FY, 2017

Cash

273.1m340.7m

Accounts Receivable

6.5m10.5m

Inventories

1.8m

Current Assets

281.3m354.8m
Quarterly
Annual
USDFY, 2016FY, 2017

Net Income

(10.6b)(67.5m)

Depreciation and Amortization

3.0k3.0m

Inventories

(285.0k)

Accounts Payable

163.0k(488.0k)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(6.7m)(13.6m)(21.1m)(12.6m)(28.2m)(43.6m)(21.4m)(43.6m)(66.3m)

Depreciation and Amortization

187.0k434.0k699.0k660.0k1.4m2.2m1.0m2.1m3.2m

Accounts Payable

(87.0k)(367.0k)154.0k(954.0k)(670.0k)(232.0k)59.0k(1.6m)(65.0k)

Cash From Operating Activities

(9.4m)58.1m50.5m(11.4m)(27.1m)(44.0m)(17.8m)(40.3m)(52.7m)
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

Intellia Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

Intellia Therapeutics News and Updates

Intellia Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Developments

CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced financial results and operational developments for the third …

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2018 Earnings and Corporate Developments

CAMBRIDGE, Mass., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present third quarter 2018 results and corporate developments in a…

Intellia Therapeutics Names Glenn Goddard as New Chief Financial Officer

CAMBRIDGE, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, has named Glenn Goddard its executive vice president and chief financia…

CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology

ZUG, Switzerland and CAMBRIDGE, Mass. and BERKELEY, Calif., Sept. 10, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (NASDAQ:CRSP), Intellia Therapeutics, Inc. (NASDAQ:NTLA) and Caribou Biosciences, Inc. announced that the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit”) affi…

Intellia Therapeutics Presents Progress in Lead In Vivo Program at Cold Spring Harbor Laboratory’s Fourth Meeting on Genome Engineering: The CRISPR-Cas Revolution

  Robust, dose-responsive liver editing and reduction of TTR protein shown  in humanized mouse model

Intellia Therapeutics Announces Second Quarter 2018 Financial Results

CAMBRIDGE, Mass., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, announced financial results and operational progress for the second quarter of 2018.
Show more
Report incorrect company information

Intellia Therapeutics Blogs

Intellia Therapeutics to Present at November Healthcare Investor Conferences

Intellia Therapeutics to Present at November Healthcare Investor Conferences Content Import Thu, 11/08/2018 - 16:34 Intellia Therapeutics to Present at November Healthcare Investor Conferences Nov 8, 2018 This release is a backfill from a Ne…

Jesse Goodman, M.D.

Jesse Goodman, M.D. John.Bissaillo… Mon, 11/05/2018 - 11:50 Jesse Goodman, M.D, Director Independent Director

Martin Auster from Credit Suisse to our alphabetical analyst coverage list? His email is martin.auster@credit-suisse.com

Martin Auster from Credit Suisse to our alphabetical analyst coverage list? His email is martin.auster@credit-suisse.com John.Bissaillo… Mon, 10/29/2018 - 07:54 Martin Auster Credit Suisse martin.auster@credit-suisse.com

Intellia Therapeutics Presents New Data in In Vivo and Ex Vivo Programs at the 26th Annual Congress of the European Society of Gene and Cell Therapy

Intellia scientists present first robust demonstration of CRISPR-mediated insertion of  transgenes in the liver Non-human primate data show high correlation achieved between  liver edit and reduction of TTR protein High rate and specificity of acute myeloid leukemia cell killing observed  with

Intellia Therapeutics to Present at October Healthcare Investor Conferences

Intellia Therapeutics to Present at October Healthcare Investor Conferences Content Import Mon, 09/24/2018 - 08:33 Intellia Therapeutics to Present at October Healthcare Investor Conferences Sep 24, 2018 This release is a backfill from a N…

Raymond James – Steven Seedhouse - Steve.Seedhouse@RaymondJames.com

Raymond James – Steven Seedhouse - Steve.Seedhouse@RaymondJames.com John.Bissaillo… Fri, 09/21/2018 - 07:36 Steven Seedhouse Raymond James Steve.Seedhouse@RaymondJames.com

Intellia Therapeutics Company Life and Culture

Report incorrect company information

Intellia Therapeutics Frequently Asked Questions

  • When was Intellia Therapeutics founded?

    Intellia Therapeutics was founded in 2014.

  • Who are Intellia Therapeutics key executives?

    Intellia Therapeutics's key executives are Nessan Bermingham.

  • How many employees does Intellia Therapeutics have?

    Intellia Therapeutics has 104 employees.

  • Who are Intellia Therapeutics competitors?

    Competitors of Intellia Therapeutics include Aevi Genomic Medicine, Ultragenyx Pharmaceutical and Illumina.

  • Where is Intellia Therapeutics headquarters?

    Intellia Therapeutics headquarters is located at 40 Erie St Ste 130, Cambridge.

  • Where are Intellia Therapeutics offices?

    Intellia Therapeutics has an office in Cambridge.

  • How many offices does Intellia Therapeutics have?

    Intellia Therapeutics has 1 office.